Respiratory Failure

Attention Site Visitor

You are currently visiting the UI Health Care Clinical Trials website on a version of the web browser: Internet Explorer. Internet Explorer is no longer being supported by Microsoft, and there are features and functionality on this website that does not operate properly when using Internet Explorer. If you have an alternative browser, such as: Microsoft Edge, Google Chrome, Mozilla Firefox, or Apple Safari, we suggest you switch to that browser for the optimal viewing experience.

Thank you

Auxora for the Treatment of AKI and Modulation of Injurious Crosstalk with the Lung: A Randomized Control Trial (KOURAGE)

Internal Medicine Nephrology Pulmonology Endocrinology Kidney Disease Respiratory Distress Syndrome Respiratory Failure Kidney Failure Diabetes Adult Subjects

Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.

Attention Site Visitor

Auxora for the Treatment of AKI and Modulation of Injurious Crosstalk with the Lung: A Randomized Control Trial (KOURAGE)

Auxora for the Treatment of AKI and Modulation of Injurious Crosstalk with the Lung: A Randomized Control Trial (KOURAGE)